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Near-infrared fluorescence imaging in the 1500–1700 nm sub-window (NIR-IIb) has shown a deeper
penetration depth, higher resolution and zero auto-fluorescence for biomedical imaging. Till now, very
few small molecule NIR-IIb fluorophores have been reported due to the extremely rare organic NIR-IIb
skeleton and a notorious aggregation-caused quenching (ACQ) effect in aqueous solution. In this study,
highly twisted NIR-II small molecule fluorophores such as HL3 (45.5 at the S0 state) with the emission
wavelength extending into the NIR-IIb region were designed and synthesized using an aggregation-
induced emission (AIE) strategy. HL3 dots showed a remarkable increase in fluorescence intensity with
a QY of 11.7% in the NIR-II window (>1000 nm) and 0.05% in the NIR-IIb region (>1550 nm) in water.
High-resolution in vivo imaging of the whole body, cerebral vasculature, and lymphatic drainage beyond
1550 nm was achieved using NIR-II AIE HL3 dots for the first time. These attractive results may promote
the development of small-molecule NIR-IIb fluorophores with the maximum emission wavelength
beyond 1500 nm with a deeper penetration depth and higher resolution.Introduction
Optical uorescence imaging is a promising modality for real-
time monitoring of disease progression, drug delivery and
image-guided surgery with high spatial and temporal resolu-
tion.1 However, traditional uorescence imaging techniques
mostly focused on the visible and near-infrared region below
900 nm, where imaging resolution and penetration depths were
largely limited due to the photo-scattering, auto-uorescence
and absorption of biological tissues. Hence, developing novel
uorophores with longer emission wavelengths to improve
imaging resolution for in vivo deeper imaging is crucial and still
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f Chemistry 2020During the past few years, molecular imaging in the second
near-infrared region (NIR-II, 1000–1700 nm) has emerged as
a powerful tool for the delineation and treatment of cancers.3–12
The rst organic small-molecule dye CH1055 with 90% renal
excretion for NIR-II bio-imaging was reported in 2015,5 and
opened up a new era for small molecule imaging. Deeper
imaging depths (up to 3 cm), excellent temporal and spatial
resolutions (50 FPS and 1 mm), and a higher tumor-to-normal
tissue (T/NT) ratio (up to 15) were achieved in the NIR-II
region.5,12 Especially, the NIR-IIb sub-window (1500–1700 nm)
showed tremendous advantages of near-zero auto-uorescence,
negligible scattering, and unparalleled tissue-imaging depths,
and turned out to be a hot spot for in vivo uorescence bio-
imaging.13 Very few inorganic NIR-IIb uorophores such as
single-walled carbon nanotubes (SWNTs), rare earth doped
nanoparticles, and quantum dots have been investigated for
biosensing and bioimaging beyond 1500 nm.7g,8f,13–17 It is worth
noting that organic FD-1080 J-aggregates were rst accom-
plished with high resolution imaging of the cerebral and hin-
dlimb vasculature with uorescence emission tailing into 1500
nm with a quantum yield (QY) of 0.0545%.17 The signal-to-
background ratio (SBR) was 3.3-fold higher than that of NIR-IIa
(1300–1400 nm) imaging. However, small-molecule NIR-IIb
uorophores (beyond 1500 nm) are still in their infancy. Shi-
ing small-molecule NIR-II uorophore emissions, specically
into the NIR-IIb sub-window, is a great challenge but crucial for
their expansion to in vivo biomedical applications. Thus, it isChem. Sci., 2020, 11, 2621–2626 | 2621

























































































View Article Onlineimperative to pursue new sorts of small molecule NIR-IIb dyes
for enhanced optical imaging.
Here, we have rationally designed and synthesized new
uorescent probes HL1–HL3 based on our previously reported
NIR-II uorophores H17d and Q4.6a The hexyloxy chain
substituted at positions R1 and R2 of thiophene not only served
as a strong donor, but also signicantly increased the dihedral
angle up to 45.5 between BBTD and thiophene for the S0
geometries (Fig. 1). Among them, HL3 showed remarkable
brightness, excellent AIE features with uorescence emission
stretching to 1550 nm and with a quantum yield of 0.05%.
Furthermore, in vivo imaging beyond 1550 nm of the blood
vessels, cerebral vasculature, and lymph nodes was achieved for
the rst time.
Results and discussion
A vast majority of small-molecule NIR-II contrast agents were
synthesized using the donor–acceptor–donor (D–A–D) back-
bones, in which benzobisthiadiazole (BBTD) was used as the
electron acceptor unit.3–13 Nevertheless, the uorescence
quantum yields of organic NIR-II chromophores in aqueous
solution were relatively low. The rigid planar aromatic struc-
tures with tremendous intermolecular p–p stacking interac-
tions and the dominant non-radiative decay may be attributed
to the aggregation-caused quenching (ACQ) effect in low-
bandgap materials.18 A feasible solution is to fully use the
brightness of the dihedral twisted NIR-II backbones with
strong emission extending into the NIR-IIb region by the
aggregation-induced emission (AIE) strategy.18–22 Thus, three
novel organic small-molecule NIR-II uorophores HL1–HL3
were designed (Fig. 1). 3,4-bis(hexyloxy)thiophene served as the
rst donor (D1), and triphenylamine was utilized as the second
donor (D2) and a building block of AIEgens. In addition, the
inuence of the electron-withdrawing group nitrobenzene and
the electron donating group aminobenzene on the whole
backbone was also investigated. Density functional theory
(DFT) was rst employed to calculate the electronic properties
of HL1–HL3 using Gaussian 09 soware and the B3LYP/6-
31G(d) method. For the optimized ground state (S0) geometries,
the twisted angles of HL1–HL3, H1 and Q4 were calculated. All
dihedral angles of HL1–HL3 between BBTD and donor 3,4-
bis(hexyloxy)thiophene were 45 (Fig. 1), exhibiting more
distortion than that of Q4 (1.9) andH1 (0.3) (Fig. S1†). TheFig. 1 The chemical structure and optimized ground state geometries
(S0) of HL1–HL3 by using the Gaussian 09 software.
2622 | Chem. Sci., 2020, 11, 2621–2626Egap of HL1 (1.78 eV) indicated short wavelength infrared
characteristics (Table S1†). Moreover, the Egap of HL2 and HL3
was 1.45 eV and 1.48 eV, respectively (Fig. S2†), lower than that
of CH1055 (1.5 eV) with a typical NIR-II optical Egap, resulting in
a hypsochromic shi compared toH1 (1.21 eV) andQ4 (1.12 eV)
(Table S1†).
The small-molecule uorophoresHL1–HL3were synthesized
mainly through Stille coupling, Zn reduction, N-thionylaniline-
induced ring closure and Suzuki coupling in 45–50% yield over
4 steps from compound 1 (Fig. 2 and ESI†). The structures were
conrmed by 1H NMR, 13C NMR, MALDI-TOF-MS or ESI-MS
(Fig. S12–S26†). The spectroscopic properties of HL1–HL3 in
THF are shown in Fig. 3B and C, and it was found that their
maximum emission wavelengths were 922 nm, 1062 nm and
1050 nm, respectively, which were consistent with the results of
Egap calculated using the Gaussian 09 soware and 6-31G(d, p).
HL3 exhibited a remarkable increase in uorescence intensity
with a strong tail in the 1500 nm region (Fig. 3C). The molar
extinction coefficients (3) of HL1–HL3 in THF were measured to
be 8.3  103 L mol1 cm1, 4.1  103 L mol1 cm1 and 7  103
L mol1 cm1, respectively. The QYs of HL1–HL3 in THF were
measured to be 0.2%, 0.34% and 2% with IR-26 (QY: 0.5%) as
a reference, respectively (Fig. S3†). The AIE properties of HL1–
HL3 were studied in the THF/water mixture solvents upon
increasing the water volume fraction (fw). As shown in Fig. 3A,
HL3 exhibited extremely strong uorescence emission in THF/
water with 90% fw. To further conrm the AIE properties of
HL1–HL3, the uorescence emission spectra with different fws
were subsequently obtained under 808 nm excitation (Fig. 3D, E
and S4†). The uorescence (FL) intensity of HL1–HL3 gradually
decreased with the increase of fw from 0 to 40–50%, and
increased sharply for HL3 from fw 50% to 90%, indicating
a typical AIE characteristic. Meanwhile, no AIE characteristics
were observed for H1 and Q4 under the similar conditions.
HL2 and HL3 dots with high monodispersity and homoge-
neity were prepared in amphiphilic DPPE-5KPEG (Fig. 4A, S5
and S6†). HL3 dots were characterized for bioimaging applica-
tions by transmission electronmicroscopy (TEM), dynamic light
scattering (DLS) and the zeta potential with an average size of
90 nm, a dynamic size of 120 nm (Fig. 4B) and  9.2 eV,
respectively (Fig. S7†). The encapsulation efficiency of HL3 dots
was calculated to be82% (Fig. S8†). The maximum absorption
wavelength was 750 nm (Fig. 4C). The maximum emission
wavelength was centered at 1050 nm and tailed to 1600 nmFig. 2 The synthetic routes of HL1–HL3. Reagents and conditions: (a)
Pd(PPh3)4 and THF; (b) Zn, NH4Cl, and CH2Cl2/MeOH/H2O; (c) PhNSO,
TMSCl, and pyridine, two steps; (d) NBS, HBr, and DMF/CH3CN; (e)
PdCl2(dppf)2CH2Cl2 and K2CO3.
This journal is © The Royal Society of Chemistry 2020
Fig. 3 (A) NIR-II fluorescence images (1000 LP, 808 nm excitation, 40
mW cm2, and 5 ms) of HL1–HL3 in THF and THF/water (fw 90%); (B)
absorption and (C) fluorescence emission spectra of HL1–HL3 in THF
under 808 nm excitation; (D) fluorescence emission spectra of HL3
obtained upon increasing fw from 0 to 90% under 808 nm excitation;
(E) fluorescence intensity ratios (I/I0) of HL1–HL3 in different fws, I0 is
the fluorescence intensity of HL1–HL3 in THF.
Fig. 4 (A) The formation ofHL3 dots via nanoprecipitation; (B) the DLS
and TEM images of the HL3 dots, scale bar: 100 nm; (C) the absorption
spectra of HL3 dots in water; (D) the fluorescence spectra of HL3 dots,
inset: NIR-IIb image of HL3 dots (1550 nm LP, 808 nm excitation, 90
mW cm2, and 500 ms exposure time) at a concentration of 0.3 mg
mL1 in water; (E) the photo-stability of HL3 dots in water, FBS, PBS
and ICG in PBS with continuous 808 nm laser irradiation for 60min (90
mW cm2); (F) the cytotoxicity of HL3 dots.

























































































View Article Online(Fig. 4D). The quantum yields were calculated to be 11.7% in
the NIR-II region (1000–1700 nm) and 0.05% in the NIR-IIb
region (beyond 1550 nm). The molar extinction coefficient (3) of
HL3 dots in water was measured to be 9.3  103 L mol1 cm1.
The reasonable quantum yields and NIR-IIb uorescence
emission of HL3 dots encouraged us to explore their NIR-IIb
imaging capabilities in vitro. HL3 dots exhibited excellent
uorescence intensity beyond 1550 nm under 808 nm laser
irradiation (1550 nm LP, Fig. 4D). As shown in Fig. 4E, the
uorescence intensity of the HL3 dots showed no obvious
changes in different media (FBS, PBS and water) under
continuous 808 nm laser irradiation for 1 h (90 mW cm2). L929
mouse broblast cells were applied to evaluate the potential
cytotoxicity ofHL3 dots using a standard 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. High cell
viability was observed even at a high concentration (100 mg
mL1, Fig. 4F). The pharmacokinetics of HL3 dots were also
investigated through the measurement of the blood circulation
half-life. The blood half-life of HL3 dots was 114 min (Fig. S9†).
All these results have demonstrated thatHL3 dots have superior
stability and excellent biocompatibility, and are more appli-
cable for NIR-IIb bioimaging (beyond 1550 nm) in vivo.
To explore the feasibility of HL3 dots as a novel AIE NIR-IIb
probe for reliable imaging of the whole body and cerebral
vasculature system in KM mice and C57BL/6 mice (n ¼ 3 per
group), HL3 dots (200 mL, 1 mg mL1) were then injected into
KM mice via the tail vein, and NIR-II and NIR-IIb images of
blood vessels were recorded using an InGaAs camera withThis journal is © The Royal Society of Chemistry 2020different LP lters (1000 nm, 1250 nm, and 1550 nm) and
different exposure times under 808 nm laser irradiation (90
mW cm2). Aer 5 min post-injection, whole blood vessels
were clearly visualized, and the hind limb vasculature was
chosen for analysis via the Gaussian-tted full width at half
maximum (FWHM) (Fig. 5). It was found that the imaging of
HL3 dots in the NIR-II window (>1250 nm, 1250 nm LP) with
a 50 ms exposure time exhibited highly superior resolution
(Fig. 5B). An extended exposure time (500 ms) was needed for
higher resolution NIR-IIb imaging beyond 1550 nm (>1550 nm,
1550 nm LP) (Fig. 5C). The FWHM values of the hind limb
vasculature were 777 mm (1000 nm LP), 768 mm (1250 nm LP)
and 719 mm (1550 nm LP), respectively. The signal-to-back-
ground ratio (SBR) of NIR-IIb imaging (SBR ¼ 2.5, 1550 nm LP)
was much higher than that of NIR-II imaging (SBR ¼ 1.4, 1000
nm LP and SBR ¼ 1.8, 1250 nm LP) (Fig. 5). The cerebral
vasculature system was also imaged using the NIR-IIb probe
HL3 dots. The superior resolution of tiny vessels was obtained
(Fig. 6). The corresponding SBR of NIR-II 1000 nm, NIR-II 1250
nm and NIR-IIb 1550 nm imaging was 1.4, 1.8 and 3.4,
respectively (Fig. 6D and E). The SBR of NIR-IIb imaging (1550
nm LP) was 2.4-fold higher than that of NIR-II imaging (1000
nm LP). The FWHM values of the vessels at the same position
(red dashed line) for different LP lters were calculated to beChem. Sci., 2020, 11, 2621–2626 | 2623
Fig. 5 NIR-II and NIR-IIb fluorescence images of whole mouse blood
vessels after tail intravenous injection of HL3 dots (200 mL, 1 mg mL1)
under 808 nm laser excitation (90 mW cm2) with different long-pass
filters (left to right: 1000 nm, 1250 nm and 1550 nm). Scale bar (A–C): 1
cm. (A) 1000 nm LP, 5 ms exposure time, and 90 mW cm2; (B) 1250
nm LP, 50 ms exposure time, and 90 mW cm2; (C) 1550 nm LP, 500
ms exposure time, and 90 mW cm2; (D–F) the fluorescence intensity
profiles fitted using Gaussian, cross-section intensity (blue line), blue-
dashed lines (1000 nm), green-dashed lines (1250 nm), red-dashed
lines (1550 nm).
Fig. 6 NIR-II and NIR-IIb fluorescence images of cerebral vasculature
with different LP filters in C57BL/6 mice (n ¼ 3) after tail intravenous
injection of HL3 dots (200 mL, 1.5 mgmL1). Scale bars (A–C): 1 cm. (A)
1000 nm LP, 4 ms exposure time, and 90 mW cm2; (B) 1250 nm LP,
60 ms exposure time, and 90 mW cm2; (C) 1550 nm LP, 500 ms
exposure time, and 90 mW cm2; (D–F) the fluorescence intensity
profiles fitted using Gaussian, cross-section intensity (black lines), and
the tiny vessel (red-dashed lines).
Fig. 7 Dynamic NIR-IIb imaging of lymphatic drainage in KM normal
mice (n ¼ 3) after injection of HL3 dots (15 mL, 1 mg mL1) under 808
nm laser excitation (1550 nm LP, 500 ms, and 90 mW cm2). (A) The
digital photograph and in vivoNIR-II fluorescence imaging at 0min; (B)
1 min; (C) 30 min; (D) 1 h; (E) 3 h after injection. (F) The fluorescence
intensity profiles fitted using Gaussian in (D), cross-section intensity
(black line) and the lymphatic vessel (white-dashed lines).

























































































View Article Online701 mm (1000 nm LP), 687 mm (1250 nm LP), and 562 mm (1550
nm LP), respectively. The NIR-II uorescence images obtained
using 1000 nm, 1250 nm and 1550 nm LP were also evaluated
at the same exposure time (200 ms) at a concentration of 0.8
mg mL1. It was found that HL3 saturated the detector with
1000 nm and 1250 nm long-pass lters under imaging condi-
tions suitable for HL3 with a 1550 nm long-pass lter
(Fig. S10†). All these results indicated that HL3 dots have great
potential for in vivo NIR-IIb imaging (beyond 1500 nm) at an
extended exposure time.
The lymph node drainage plays a vital role in tumor metas-
tasis. We next demonstrated the application of HL3 dots for2624 | Chem. Sci., 2020, 11, 2621–2626lymph node NIR-IIb imaging (beyond 1550 nm). HL3 dots (15
mL, 1 mg mL1) were injected intra-dermally at the le forefoot
pad of KM mice (n ¼ 3 per group) (Fig. 7). The process of
lymphatic drainage was monitored under 808 nm laser irradi-
ation (90 mW cm2) using 1550 nm LP. Lymphatic vessels were
notably identied in 1 min aer injection. The popliteal lymph
node was gradually lighted up, and both the popliteal lymph
node and the subiliac lymph node were clearly visualized in 2 h.
The diameter of the lymphatic vessel between the popliteal
lymph node and the subiliac lymph node was calculated to be
533 mm via FWHM, and the SBR reached 4 (Fig. 7F). The SBR
values of the popliteal lymph node and the subiliac lymph node
were 2.5 and 3.2 (1000 nm LP), 2.9 and 3.4 (1250 nm LP), and 5.1
and 4.8 (1550 nm LP), respectively (Fig. S11†). These results
reveal that NIR-IIb imaging beyond 1550 nm of lymph node
drainage can be achieved with a higher SBR.Experimental section
All animal experiments were performed according to the
Chinese Regulations for the Administration of Affairs Con-
cerning Experimental Animals and approved by the Institu-
tional Animal Care and Use Committee (IACUC) of Wuhan
University. And all the experimental details are provided in the
ESI.†Conclusions
In summary, we have successfully synthesized a series of small
molecule uorophores HL1–HL3 by introducing different
donors and distortion groups. Among them, HL3 showed
extremely stronger AIE characteristics and highly twisted
donor–acceptor distortion. HL3 dots exhibited excellent water
solubility, photo-stability and biocompatibility with a remark-
able increase in NIR-II uorescence intensity with QYs of 11.7%This journal is © The Royal Society of Chemistry 2020

























































































View Article Onlineand 0.05% in the NIR-II (>1000 nm) and NIR-IIb region (>1550
nm), respectively, in water. Superior quality NIR-IIb imaging
beyond 1550 nm of the whole body, cerebral vasculature and the
lymphatic drainage system was demonstrated for the rst time
with a higher SBR. It is hoped that this novel NIR-II uorophore
HL3 obtained using an integrated AIE and D–A distortion
strategy may become a practical strategy to develop small-
molecule NIR-IIb uorophores with the maximum emission
wavelength beyond 1500 nm with a deeper penetration depth
and higher resolution.Conflicts of interest
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